Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy

Journal of Clinical Investigation

Volumn 102, Issue 4, 1998, Pages 671-678

  Comabella, Manuel ^a   Balashov, Konstantine ^a   Issazadeh, Shohreh ^a   Smith, Derek ^a   Weiner, Howard L ^a   Khoury, Samia J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cyclophosphamide; Interleukin 12; Intracellular immunofluorescence; Multiple sclerosis; Th2; Th3

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; METHOTREXATE; METHYLPREDNISOLONE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CELL LABELING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE MARKER; DRUG EFFECT; DRUG INDICATION; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 0032528896     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI3125     Document Type: Article

References (49)

1. Khoury, S.J., H.L. Weiner, and D.A. Hafler. 1996. Immunological mechanisms in multiple sclerosis. In Handbook of Multiple Sclerosis. S.D. Cook, editor. Marcell Dekker Inc., New York. 145-155.
2. Mosmann, T.R., H. Cherwinski, M.W. Bond, M.A. Giedlin, and R.L. Coffman. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136: 2348-2357.
3. Chen, Y., V.K. Kuchroo, J.-I. Inobe, D.A. Hafler, and H.L. Weiner. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 265:1237-1240.
4. Weiner, H.L. 1997. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today. 18:335-343.
5. Ando, D.G., J. Clayton, D. Kono, J.L. Urban, and E.E. Sercarz. 1989. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell. Immunol. 124:132-143.
6. Racke, M.K., A. Bonomo, D.E. Scott, B. Cannella, A. Levine, C.S. Raine, E.M. Shevach, and M. Rocken. 1994. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp. Med. 180:1961-1966.
7. Khoury, S.J., W.W. Hancock, and H.L. Weiner. 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176:1355-1364.
8. Kennedy, M.K., D.S. Torrance, K.S. Picha, and K.M. Mohler. 1992. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:2496-2505.
9. Issazadeh, S., A. Ljungdahl, B. Hojeberg, M. Mustafa, and T. Olsson. 1995. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin 10, interleukin 12, cytolysin, tumor necrosis factor-a and tumor necrosis factor-b. J. Neuroimmunol. 61:205-212.
10. Chen, Y., W.W. Hancock, R. Marks, P.A. Gonnella, and H.L. Weiner. 1998. Mechanisms of recovery from experimental allergic encephalomyelitis: T cell deletion and immune deviation in myelin basic protein receptor transgenic mice. J. Neuroimmunol. 82:149-159.
11. Manetti, R., P. Parronchi, M.G. Giudizi, M.P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199-1204.
12. Manetti, R., F. Gerosa, M.G. Giudizi, R. Biagiotti, P. Parronchi, M.P. Piccinni, S. Sampognaro, E. Maggi, S. Romagnani, G. Trinchieri, et al. 1994. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J. Exp. Med. 179:1273-1283.
13. Seder, R.A., R. Gazzinelli, A. Sher, and W.E. Paul. 1993. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA. 90:10188-10192.
14. Hsieh, C.S., S.E. Macatonia, C.S. Tripp, S.F. Wolf, A. O'Garra, and K.M. Murphy. 1993. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 260:547-549.
15. Leonard, J.P., K.E. Waldburger, and S.J. Goldman. 1995. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181:381-386.
16. Balashov, K.E., D.R. Smith, S.J. Khoury, D.A. Hafler, and H.L. Weiner. 1997. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc. Natl. Acad. Sci. USA. 94:599-603.
17. Nicoletti, F., F. Patti, C. Cocuzza, P. Zaccone, A. Nicoletti, R. DiMarco, and A. Reggio. 1996. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J. Neuroimmunol. 70:87-90.
18. Paterson, P.Y., and M.A. Hanson. 1969. Cyclophosphamide inhibition ot experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats. J. Immunol. 103:1311-1316.
19. Paterson, P.Y., and D.G. Drobish. 1969. Cyclophosphamide: effect on experimental allergic encephalomyelitis in Lewis rats. Science. 165:191-192.
20. Brinkman, C.J., W.M. Nillesen, and O.R. Hommes. 1984. The effect of cyclophosphamide on T lymphocytes and T lymphocyte subsets in patients with chronic progressive multiple sclerosis. Acta Neurol. Scand. 69:90-96.
21. Moody, D.J., J.L. Fahey, E. Grable, G.W. Ellison, and L.W. Myers. 1987. Administration of monthly pulses of Cyclophosphamide in multiple sclerosis patients. Delayed recovery of several immune parameters following discontinuation of long-term cyclophosphamide treatment. J. Neuroimmunol. 14: 175-182.
22. Lamers, K.J., B.M. Uitdehaag, O.R. Hommes, W. Doeshurg, R.A. Wevers, and W.J. von Geel. 1988. The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 51:1334-1337.
23. Hafler, D.A., J. Orav, R. Gertz, L. Stazzone, and H.L. Weiner. 1991. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J. Neuroimmunol. 32:149-158.
24. Hauser, S.L., D.M. Dawson, J.R. Lehrich, M.F. Beal, S.V. Kevy, R.D. Propper, J.A. Mills, and H.L. Weiner. 1983. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 308:173-180.
25. Weiner, H.L., G.A. Mackin, E.J. Orav, D.A. Hafler, D.M. Dawson, Y. LaPierre, R. Herndon, J.R. Lehrich, S.L. Hauser, A. Turel, et al. 1993. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 43:910-918.
26. Group., T.C.C.M.S.S. 1991. The Canadian Cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet. 337:442-446.
27. Smith, D.R., K.E. Balashov, D.A. Hafler, S.J. Khoury, and H.L. Weiner. 1997. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann. Neurol. 42:313-318.
28. Takashima, H., D. Smith, H. Fukaura, S. Khoury, D. Hafler, and H. Weiner. 1998. Pulse cyclophosphamide plus methylprednisolone induces myelin antigen specific IL-4 secreting T cells in multiple sclerosis patients. Clin. Immunol. Immunopathol. 88:28-34.
29. Lewis, C.E. 1991. Detecting cytokine production at the single-cell level. Cytokine. 3:184-188.
30. Prussin, C. 1997. Cytokine flow cytometry: understanding cytokine biology at the single-cell level. J. Clin. Immunol. 17:195-204.
31. Jung, T., U. Schauer, C. Heusser, C. Neumann, and C. Rieger. 1993. Detection of intracellular cytokines by flow cytometry. J. Immunol. Meth. 159:197-207.
32. Link, J., M. Soderstrom, T. Olsson, B. Hojeberg, A. Ljungdahl, and H. Link. 1994. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann. Neurol. 36:379-386.
33. Panitch, H.S., R.L. Hirsch, A.S. Haley, and K.P. Johnson. 1987. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1:893-895.
34. Beck, J., P. Rondot, L. Catinot, E. Falcoff, H. Kirchner, and J. Wietzerbin. 1988. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestations in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol. Scand. 78:318-323.
35. Olsson, T., W.-Z. Wang, B. Höjeberg, V. Kostulas, Y.-P. Jiang, G. Anderson, H.-P. Ekre, and H. Link. 1990. Autoreactive T-lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J. Clin. Invest. 86:981-985.
36. Blotta, M.H., R.H. DeKruyff, and D.T. Umetsu. 1997. Corticosteroids inhibit H.-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J. Immunol. 158:5589-5595.
37. Crucian, B., P. Dunne, H. Friedman, R. Ragsdale, S. Pross, and R. Widen. 1996. Detection of altered T helper 1 and T helper 2 cytokine production by peripheral blood mononuclear cells in patients with multiple sclerosis utilizing intracellular cytokine detection hy flow cytometry and surface marker analysis. Clin. Diagn. Lab. Immunol. 3:411-416.
38. Scheinman, R.I., P.C. Cogswell, A.K. Lofquist, and A.J. Baldwin. 1995. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 270:283-286.
39. Auphan, N., J.A. DiDonato, C. Rosette, A. Helmberg, and M. Karin. 1995. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 270:286-290.
40. Ramirez, F., D.J. Fowell, M. Puklavec, S. Simmonds, and D. Mason. 1996. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J. Immunol. 156:2406-2412.
41. Zieg, G., G. Lack, R.J. Harbeck, E.W. Gelfand, and D.Y. Leung. 1994. In vivo effects of glucocorticoids on IgE production. J. Allergy Clin. Immunol. 94:222-230.
42. Racke, M.K., S. Dhib-Jalbut, P.S. Cannella, P.S. Albert, and D.E. McFarlin. 1991. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. J. Immunol. 146:3012-3017.
43. Johns, L., K. Flanders, G. Ranges, and S. Sriram. 1991. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-β1. J. Immunol. 147:1792-1796.
44. Olsson, T. 1995. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev. 144:245-268.
45. Marth, T., W. Strober, R.A. Seder, and B.L. Kelsall. 1997. Regulation of transforming growth factor-beta production by interleukin-12. Eur. J. Immunol. 27:1213-1220.
46. Diamantstein, T., M. Klos, H. Hahn, and S.H. Kaufmann. 1981. Direct in vitro evidence for different susceptibilities to 4-hydroperoxycyclophosphamide of antigen-primed T cells regulating humoral and cell-mediated immune responses to sheep erythrocytes: a possible explanation for the inverse action of cyclophosphamide on humoral and cell-mediated immune responses. J. Immunol. 126:1717-1719.
47. Kaufmann, S.H., H. Hahn, and T. Diamantstein. 1980. Relative susceptibilities of T cell subsets involved in delayed-type hypersensitivity to sheep red blood cells to the in vitro action of 4-hydroperoxycyclophosphamide. J. Immunol. 125:1104-1108.
48. Cella, M., D. Scheidegger, L.K. Palmer, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747-752.
49. DeKruyff, R.H., R.S. Gieni, and D.T. Umetsu. 1997. Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. J. Immunol. 158:359-366.